FDA Clears New Form of Latanoprost for Glaucoma

The US Food and Drug Administration (FDA) has approved latanoprostophthalmic emulsion 0.005% (Xelpros, Sun Pharmaceuticals) to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, the company has announced.

Xelpros is the first and only form of latanoprost that is not formulated with benzalkonium chloride (BAK), a preservative commonly used in topical ocular preparations, the company said.

For more information: https://www.medscape.com

Related Articles

Share on facebook
Share on whatsapp
Share on email